Amy Anderson, DO
Endocrinology, Diabetes & Metabolism · Fall River, MANPI 1366603128
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,543 and has fallen 80.3% since, to $304 in 2025.
Across 221 payments — averaging $24.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$937
- Amgen$473
- Boehringer Ingelheim$430
- Lilly USA, LLC$420
- Abbott$418
- Sanofi-aventis U.S. LLC$385
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,22298%
- Education$541%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 24 | $937 |
| Amgen | 18 | $473 |
| Boehringer Ingelheim | 18 | $430 |
| Lilly USA, LLC | 23 | $420 |
| Abbott | 22 | $418 |
| Sanofi-aventis U.S. LLC | 11 | $385 |
| Novo Nordisk | 17 | $347 |
| AstraZeneca | 15 | $288 |
| Medtronic(2 entities) | 5 | $170 |
| Mannkind Corporation | 5 | $165 |
| Insulet Corporation | 7 | $156 |
| Tandem Diabetes Care, Inc. | 4 | $146 |
| Lifescan, Inc. | 6 | $130 |
| AbbVie | 6 | $116 |
| Bayer | 5 | $112 |
| Dexcom, Inc. | 5 | $85 |
| Johnson & Johnson | 4 | $70 |
| Valeritas, Inc. | 3 | $65 |
| Radius Health, Inc. | 3 | $51 |
| Johnson & Johnson Vision Care, Inc. | 2 | $50 |
| Amarin Pharma, Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Nevro Corp. | 2 | $39 |
| IBSA Pharma Inc. | 2 | $29 |
| Pfizer | 2 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Companion Medical, Inc. | 1 | $22 |
| Acerus Pharmaceuticals Corporation | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Cequr Corporation | 1 | $18 |
| Sobi, Inc | 1 | $16 |
| Merck | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,335 in reported general payments places this provider in the 75th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 24 | $597,914 |
| MounjaroTirzepatide | 272 | $413,638 |
| OzempicSemaglutide | 298 | $384,477 |
| JardianceEmpagliflozin | 202 | $256,735 |
| Tresiba Flextouch U-100Insulin Degludec | 297 | $176,156 |
| TrulicityDulaglutide | 151 | $172,452 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 63 | $99,173 |
| FarxigaDapagliflozin Propanediol | 111 | $90,914 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 46 | $89,390 |
| Tresiba Flextouch U-200Insulin Degludec | 63 | $87,807 |
| JanuviaSitagliptin Phosphate | 88 | $82,815 |
| ProliaDenosumab | 28 | $45,365 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 15 | $34,780 |
| TymlosAbaloparatide | 11 | $29,286 |
| Humalog Kwikpen U-200Insulin Lispro | 19 | $27,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $937 | $597,91424 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $420 | $593,246453 claims |
| Novo NordiskOzempic, Novolog, Fiasp, Tresiba | $347 | $427,233360 claims |
| Boehringer IngelheimJardiance | $430 | $256,735202 claims |
| AstraZenecaFarxiga | $288 | $90,914111 claims |
| MerckJanuvia | $13 | $82,81588 claims |
| AmgenProlia | $473 | $45,36528 claims |
| Radius Health, Inc.Tymlos | $51 | $29,28611 claims |
| Cequr CorporationCequr Simplicity | $18 | $23,97944 claims |
| AbbVieSynthroid | $116 | $14,087172 claims |
| IBSA Pharma Inc.Tirosint | $29 | $10,81034 claims |
| Sanofi-aventis U.S. LLCAdmelog | $385 | $4,85215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Fall River
- Tamer YacoubFall River$775K
- Kishore LakshmanFall River$9K
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.